Ken Reed

Ken Reed has been working in the medical field since 1984 when they started as a Dermatologist for DermAsap. In 2010, they joined the Board of Directors for RedHill Biopharma Ltd., where they helped advise and direct the company with a focus on gastrointestinal diseases, oncology, and inflammatory disorders. In 2011, Ken became the Director of Minerva Biotechnologies and in 2014 they Co-Founded Prescient Pharma LLC. Ken also joined the Scientific Advisory Board for Mybiotix in 2016, WinProbe in 2018, and Xylyx Bio, Inc. and Zen Graphene in 2021.

Ken Reed completed a Bachelor's Degree in Biology from Brown University from 1971 to 1975. Ken then went on to the College of Medicine and Dentistry of New Jersey, where they obtained their Doctor of Medicine (M.D.) degree from 1976 to 1980. Ken then did an Internship in Internal Medicine at Thomas Jefferson University Hospitals from 1980 to 1981. Lastly, they completed a Combined Residency Program in Dermatology at Harvard Medical School from 1981 to 1984.